Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Results May Vary, But Reporting Shouldn’t: FDA Sends a Not-So-Gentle Reminder on ClinicalTrials.gov Compliance
On March 30, 2026, the FDA emailed more than 2,200 sponsors and investigators linked to over 3,000 clinical trials that have not posted required results on ClinicalTrials.gov or failed quality‑control review. The agency reminded that results must be posted within one year of primary completion, yet its analysis shows roughly 30% of applicable trials remain non‑compliant. FDA emphasized that non‑reporting can stem from process breakdowns, but it also warned that it may issue Pre‑Notices and, if needed, formal Notices of Noncompliance with civil penalties. The outreach signals a more proactive enforcement stance, urging responsible parties to resolve outstanding submissions promptly.
Belite Bio Files NDA for Tinlarebant After 35.7% Lesion Reduction in Phase 3 Trial
Belite Bio began a rolling New Drug Application for tinlarebant on April 21, 2026, after its Phase 3 DRAGON trial demonstrated a 35.7% reduction in retinal lesion growth for Stargardt disease patients. The filing could accelerate approval for the first...
OZMOSI Teams with Planview to Deploy AI‑Driven Portfolio Planning for Pharma R&D
OZMOSI announced a strategic partnership with Planview, integrating its machine‑readable clinical intelligence into Planview’s AI‑driven portfolio management platform. The deal gives pharmaceutical teams access to data from more than 800,000 trials, 35,000 drugs and 4,000 diseases, promising faster, data‑backed R&D...
Philips Secures FDA Clearance for Rembra CT Platform, Boosting Frontline Imaging Speed
Philips received FDA 510(k) clearance for its Rembra CT platform, a system built for ultra‑fast, high‑throughput imaging that can handle up to 270 exams per day. The clearance expands Philips' portfolio across diagnostic radiology and radiation therapy, aiming to meet...
The Horrors That Could Lie Ahead if Vaccines Vanish
Stanford researchers modeled the health impact of a complete loss of childhood vaccines for polio, measles, rubella and diphtheria over the next 25 years. Their simulations show that even at today’s vaccination levels the U.S. is on the brink of...
Burnout in Medicine Is Still Prevalent, With Emergency Medicine Leading
A new American Medical Association report shows physician burnout modestly improving, with 41.9% reporting at least one symptom in 2025, down from 48.2% in 2023. Emergency medicine remains the most affected specialty at 49.8%, followed closely by urological surgery. The...
Cumberland Pharma’s $100 Million Sale to Apotex Affiliate Sends Stock 44% Higher
Cumberland Pharmaceuticals Inc. agreed to sell its branded U.S. drug portfolio to an affiliate of Apotex for $100 million, prompting a 44% surge in its Nasdaq‑listed shares. The deal highlights ongoing consolidation in the specialty pharma market and raises questions about...
Weight Control Depends on Calories, Not Lifelong GLP‑1
The most annoying question that everyone keeps asking me is if I have to continue to take a glp-1 for life. Stopping a glp-1 doesn't make you gain weight. Eating a calorie surplus makes you gain weight. I know exactly how...
Houston Friday Night: Comedy, Immunization Partnership Celebrate Vaccines
Friday night in HoustonTX I will be there along with The Immunization Partnership and COMEDY INJECTION, VACCINES: 9th Wonder of the World https://t.co/GPSrrB3poV https://t.co/THhFN31ebn
United Kingdom to Enact Smoking Ban Only for Those Who Are Not Yet Legal Adults
The UK Parliament approved a bill that will permanently prohibit the sale of tobacco to anyone born in 2009 or later, effectively creating a “smoke‑free generation.” The measure applies to all four nations of the United Kingdom and will take...
Are Labor’s NDIS Reforms Too Good to Be True?
The Australian government will overhaul the National Disability Insurance Scheme (NDIS) by introducing stricter eligibility criteria, announced by Health Minister Mark Butler. All 760,000 current participants will be reassessed, with a goal of removing 160,000 people from the program by...
Why Carpet Disinfectant Is Critical for Infection Control in Healthcare Facilities
Carpet surfaces in hospitals and clinics can harbor bacteria, viruses, and other pathogens deep within their fibers, turning them into hidden reservoirs of infection. While routine cleaning removes visible dirt, it does not reliably eliminate these microorganisms, making disinfection a...
Iowa Launches Pilot to Embed Mental‑Health Care in Cancer Treatment
Iowa health officials have begun a statewide pilot that integrates mental‑health screening and therapy referrals into oncology clinics. The effort targets rising cancer rates and a chronic shortage of mental‑health providers, especially in rural counties. Advocates say the model could...
Study Finds Preschoolers with Congenital Heart Defects Face Higher ADHD and Social Risks
A UK research team reported that preschoolers born with congenital heart disease (CHD) are significantly more likely to develop attention‑deficit/hyperactivity disorder and peer‑relationship difficulties. The study also found that a cognitively stimulating home can lower those odds, offering a clear...
Study Finds Rapamycin May Undermine Exercise Benefits
Researchers at the Lifespan Research Institute reported that rapamycin, a leading longevity drug, may blunt the physiological gains from regular exercise. The finding challenges the common biohacker practice of pairing rapamycin with fitness regimens and highlights a potential trade‑off between...
Hims & Hers Gains 7% on FDA Peptide Review, Faces Amazon Competition
Hims & Hers Health surged more than 7% when the FDA scheduled a July 23‑24 meeting to review several peptide drugs, giving investors a new growth narrative. The rally was later tempered as Amazon launched a competing GLP‑1 weight‑loss service,...
TCV‑Backed Kipu Health Acquires Team Recovery to Bolster Behavioral Health Platform
Kipu Health, the TCV‑backed behavioral‑health technology leader, announced the acquisition of Team Recovery Technologies, a provider serving more than 150 U.S. treatment centers. The deal expands Kipu’s platform with alumni‑engagement and referral‑growth tools, underscoring a private‑equity‑style push to consolidate health‑tech...
Spinogenix Starts CLARITY Phase 2b/3 Trial of SPG601 for Fragile X Syndrome
Spinogenix, a clinical‑stage biopharma, has launched the CLARITY trial – a two‑part Phase 2b/3 study of its oral BK‑channel modulator SPG601 in male patients with Fragile X Syndrome. The initial arm will enroll up to 48 adult males, followed by...
Molina Healthcare Beats Q1 Forecast on Cost Controls, Shares Jump 11%
Molina Healthcare reported first‑quarter adjusted earnings of $2.35 per share, surpassing analyst expectations of $1.92‑$2.17. The Medicaid‑heavy insurer credited disciplined medical‑cost management and a 91.1% consolidated medical care ratio for the beat, sending the stock up more than 11% and...
Schwab Warns Medicare Enrollment Mistake Could Drain Tens of Thousands From Retirees' Savings
Charles Schwab’s latest retirement guide warns that enrolling in Medicare at the wrong time or choosing the wrong plan can cost retirees tens of thousands of dollars. The firm outlines two strategies and key dates, stressing the importance of understanding...
Medtronic Buys CathWorks for $585M to Add AI Cardiovascular Diagnostics
Medtronic has completed a $585 million purchase of CathWorks, a private medical‑device company whose AI‑based FFRangio system offers wire‑free coronary assessment. The deal follows a 2022 partnership and recent trial data showing non‑inferior outcomes to traditional FFR, positioning Medtronic for deeper...
CVS Health Fights Tennessee FAIR Rx Act that Could Shutter 134 Pharmacies
CVS Health is challenging the Tennessee FAIR Rx Act, a law that would bar companies from owning both a pharmacy benefit manager and a pharmacy. The company says the measure could force the closure of up to 134 CVS pharmacies,...
Largest Catch-Up Initiative Delivers over 100 Million Childhood Vaccinations
The Big Catch‑Up (BCU) initiative, launched during World Immunization Week 2023, has administered more than 100 million vaccine doses to an estimated 18.3 million children in 36 low‑ and middle‑income countries. About 12.3 million of those children were zero‑dose, never having received any...
RFK Jr.’s FDA Shake‑up Sparks Biotech Uncertainty
Health Secretary Robert F. Kennedy Jr.’s overhaul of the FDA, marked by rapid leadership turnover, layoffs and recent rejections of experimental cancer therapies, has left biotech firms uneasy. The turmoil coincides with a plunge in venture capital to its lowest level in two...
The BALANCE Model Pause, the GLP-1 Bridge Extension Thru Dec 2027 & What the 80% Part D Participation Threshold Miss...
CMS announced on April 21, 2026 that the Medicare Part D component of the BALANCE anti‑obesity drug model is paused for calendar year 2027 after the required 80 percent NAMBA‑weighted enrollment threshold was not met. The GLP‑1 Bridge demonstration, which provides $50‑per‑month access outside the...
New Bioreactor Turns Stem Cells Into an Immune-Cell Factory, Producing 40 Million Human Macrophages per Week
Researchers at Hannover Medical School have unveiled a medium‑scale bioreactor that converts induced pluripotent stem cells into human macrophages at commercial‑grade volumes. The system can harvest up to 40 million immune cells per bioreactor each week for up to ten weeks,...
Meta-Analysis Flawed by Mixing Disparate Anti‑amyloid Agents
A harsh critique of the recent @cochranecollab meta-analysis of the anti-amyloid drugs for Alzheimer's disease https://t.co/EU4JMOVWkV 'These results and their overarching conclusion that “successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in...
![Silence at the Chessboard Changed How I Talk to Patients [PODCAST]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://kevinmd.com/wp-content/uploads/b664dfaa-d79f-41b8-9445-d43d50340ea4.png)
Silence at the Chessboard Changed How I Talk to Patients [PODCAST]
KevinMD’s podcast features medical students Jay Pendyala and Jonathan Berg discussing how chess shaped their clinical reasoning and humanism. They recount founding a chess club at Jefferson Medical College, using puzzles and tournaments to practice pattern recognition, foresight, and resilience....
RFK Jr. Clashes With Lawmakers Over Measles, COVID and Chronic Disease
U.S. Health Secretary Robert F. Kennedy Jr. faced back‑to‑back Senate hearings focused on measles outbreaks, declining vaccination rates, and the nation’s chronic‑disease burden, which he said drives $4.9 trillion in annual health costs. Kennedy defended the MMR vaccine, questioned flu‑shot efficacy,...
SCAN CEO Urges Brokers to Drop Plans That Treat Them Poorly — One Says She Has No Choice
At the Medicarians Conference, SCAN Health Plan CEO Sachin Jain urged brokers to abandon for‑profit Medicare Advantage plans that cut commissions and instead partner with not‑for‑profit carriers. He framed the plea as self‑interest, noting the recent 2.48% Medicare Advantage rate...
![[Comment] Alzheimer's Disease Immunotherapy and the Amyloid Hypothesis: When Aggregation Obscures Interpretation](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/614bb5987569a37ee2c14e1338f7df10.webp)
[Comment] Alzheimer's Disease Immunotherapy and the Amyloid Hypothesis: When Aggregation Obscures Interpretation
A Cochrane review released on April 16, 2026 pooled data from 17 randomized trials of amyloid‑beta‑targeting monoclonal antibodies, encompassing more than 20,000 participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The analysis found little to no...
Thursday April 23, 2026 — Field Note
Stereotaxis announced a deal to acquire robotic PCI developer Robocath for up to $45 million, including a $20 million cash upfront payment and up to $25 million in milestone‑based earn‑outs tied to regulatory and commercial progress. The acquisition brings Robocath’s R‑One+ platform—currently CE‑marked...
Brad Stanfield Rapamycin Trials
Brad Stanfield’s recent clinical study found that participants receiving a placebo performed better than those given rapamycin, a drug touted for its anti‑aging potential. The unexpected outcome was reported within hours of the trial’s completion, prompting immediate scrutiny from the...
Now Here’s a Twist: Senator Bernie Sanders and HHS Secretary Robert F. Kennedy Jr. Agree Television Ads for Junk Food...
Senator Bernie Sanders and HHS Secretary Robert F. Kennedy Jr. found common ground during an April 22 Senate Health Committee hearing, both endorsing a ban on television advertisements for junk food. Kennedy echoed Surgeon General nominee Dr. Casey Means' opposition,...
More Beds for Aged Care
The Australian government is committing roughly AU$3 billion (about US$2 billion) to aged‑care in the May budget, funding the construction of an additional 5,000 beds each year. A further AU$1 billion (≈US$660 million) will reclassify home‑care services such as showering and continence management as...
Metformin Fails to Boost Walking Distance in PAD Patients
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial "Among people with PAD without diabetes, metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support metformin...
Continuous Glucose Monitoring Outperforms Self‑Monitoring in Type 2 Diabetes
A randomized trial of continuous glucose monitoring (CGM) vs self-monitoring for Type 2 diabetes on basal insulin and drug therapies shows superiority of CGM for gluocse regulation https://t.co/XUymGiov1c @TheLancetEndo https://t.co/lcjFDnEG6x
NeurAxis (NRXS): The Pieces Are Lining Up
NeurAxis (NRXS) released preliminary Q1 data showing the first full quarter under the new Category I CPT code and expanded insurance coverage that took effect at the end of 2025. The results exceeded the analyst’s expectations, prompting a renewed bullish stance...
Executive Order on Psychedelics Discussed in New Podcast
Check out the recent podcast with @Ravarora1 about the recent executive order on psychedelics https://t.co/QwoDTN692s
Alleged FDA Pressure Removes Study Confirming Long‑term Vaccine Efficacy
Vinay Prasad forced FDA scientists to withdraw a paper from Vaccine, the journal I am co-EIC of, because it showed that COVID vaccines work for everyone 6 months+. This is Gold Standard Science at Marty Makary’s FDA. Setting the Gold...
Bipartisan Bill to Strengthen Oversight in Medicare Advantage, Ensuring Nursing Home Residents’ Care ‘Without Delay, Without Denial’
Lawmakers introduced the bipartisan Medicare Advantage Improvement Act of 2026 to tighten oversight of Medicare Advantage plans. The bill seeks to eliminate prior‑authorization delays, increase transparency, penalize non‑compliant insurers, and ban retroactive clawbacks. It also mandates automated administrative systems, prompt...
CAR‑T Turnaround: Kelonia’s LLY Deal Signals New Pharma Play
A VERY SPIRITED interview w/ Venrock VC Bryan Roberts re: Kelonia Therapeutics and its $LLY deal on this week's Readout LOUD podcast. A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts https://t.co/600DsE1cBm via @statnews
NIH Director Censors Routine Vaccine Study Over Personal Dislike
To be clear: @NIHDirector_Jay reportedly took issue with the study design, which is routine for evaluating vaccines post-market. Podcast Jay, who has no expertise in vaccine trials, decided unilaterally he didn’t like it & thus censored results of studies our...
Future Success Means Treating Revenue Cycle as a Strategic Asset, Not a Support Function
Healthcare finance leaders face mounting margin pressure, administrative complexity, and regulatory change, prompting a strategic reevaluation of the revenue cycle. AI and digital workflows are enabling a shift from fragmented, manual processes to integrated, automated cash‑flow management. The article outlines...
Bioethicist Vs. Germline Editing Entrepreneur Sparks Uneven Debate
Starting right now. Debate between I. Glenn Cohen (Harvard/reprogenetic bioethics) vs. Cathy Tie, 'serial' human germline editing startup entrepreneur. This should not be an fair fight, but Glenn Cohen is a nice guy...so https://t.co/qfqivoLvhV
4 Shifts that Define the Revenue Cycle of the Future
The future of healthcare revenue cycle management hinges on four strategic shifts: redesigning work end‑to‑end, pairing humans with AI, creating a unified AI orchestration layer, and establishing trustworthy AI governance. Rather than automating isolated tasks, leaders must rewire operating models...
Acting Attorney General Issues New DEA Order Reclassifying Some Marijuana Products as Schedule III Controlled Substances, Available by Prescription
Acting Attorney General Todd Blanche issued a final order on April 23, 2026 that reclassifies FDA‑approved cannabis medicines and state‑licensed medical marijuana products from Schedule I to Schedule III, making them available by prescription. The order requires state‑licensed dispensaries to register with...
FLAG-Based Regimen Yields Robust Results in Acute Myeloid Leukemia Subtype
A Phase 2 trial at MD Anderson evaluated FLAG‑based chemotherapy combined with either gemtuzumab ozogamicin (FLAG‑GO) or idarubicin (FLAG‑IDA) in 219 newly diagnosed core‑binding factor AML patients. The FLAG‑GO arm delivered an 80% five‑year overall survival rate and a 67% relapse‑free survival...
ESCMID Global 2026: Zelicapavir Demonstrates Benefits for High-Risk Adults with RSV
At ESCMID Global 2026, Enanta Pharmaceuticals presented Phase IIb data for zelicapavir, an oral once‑daily N‑protein inhibitor, in high‑risk adults with RSV. The double‑blind study of 186 participants missed the primary endpoint but demonstrated faster symptom resolution—up to 7 days quicker in...
Mexico Unveils National Youth Mental‑Health Strategy After School Shootings
Mexico's federal government introduced the 'ABC de las emociones' mental‑health strategy for adolescents aged 14‑18, parents, caregivers and teachers. The plan, announced after a spate of school‑related shootings, includes 18 million printed guides, a dedicated hotline and school‑based activities to address...